PanGenomic Health, Inc. Class A (NARA) AI Stock Analysis

• Market Cap: C$5.18M
• Dividend Yield: N/A
• Average Volume (3M): 14.33K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.78
• Revenue Growth: N/A
• EPS Growth: 71.97%
• Country: CA
• Employees: 5
• Sector: Healthcare
• Sector Strength: 59
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -1.73
• Shares Outstanding: 6,399,814
• 10 Day Avg. Volume: 37,341
• 30 Day Avg. Volume: 14,330
• PEG Ratio: -0.06
• Price to Book (P/B): -343.92
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -26.53
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 29 Underperform
• Price Target: ―

The overall stock score is driven by severe financial instability, with no revenue generation and increasing net losses. Technical analysis provides a mixed picture, suggesting potential short-term recovery but still reflecting overall negative momentum. The negative P/E ratio and lack of dividend yield further decrease the stock's attractiveness.

PanGenomic Health, Inc. Class A Business Overview & Revenue Model

Company Description

PanGenomic Health, Inc. Class A (NARA) is a company operating within the health and wellness sector, focusing on personalized medicine and genomics. The company provides digital health solutions that leverage genomic data to offer personalized insights and recommendations for managing mental health and wellness. Their core offerings include a mobile application platform that integrates genomic and lifestyle data to support personalized health and wellness journeys.

How the Company Makes Money

PanGenomic Health, Inc. generates revenue primarily through subscription services to its digital health platform. Users pay for access to personalized recommendations and insights based on their genomic data. Additionally, the company may earn revenue through partnerships with healthcare providers and wellness brands, offering them access to its platform for broader distribution and integration of personalized health solutions. The company may also monetize aggregated and anonymized data insights for research and development purposes in collaboration with academic and commercial partners.

PanGenomic Health, Inc. Class A Financial Statement Overview

Summary

PanGenomic Health, Inc. is in a precarious financial position with zero revenue, increasing net losses, negative equity, and reliance on external financing, indicating significant challenges in achieving financial stability and growth.

Income Statement

PanGenomic Health, Inc. has consistently reported zero revenue across all periods. The company has faced increasing net losses, with the latest TTM (Trailing-Twelve-Months) net income at -3.51 million, reflecting an unsustainable financial trajectory. The absence of revenue growth and consistent negative profit margins indicate severe challenges in achieving profitability.

Balance Sheet

The balance sheet shows negative stockholders' equity and a concerning equity deficit in the latest period, indicating that liabilities far exceed assets. Although there is no debt to equity ratio due to negative equity, the company has reduced its liabilities compared to previous years. However, the financial instability is evident with negative equity and low asset values.

Cash Flow

The cash flow statement reveals significant negative free cash flow, indicating cash outflows exceed inflows. The operating cash flow is negative, further stressing financial health. While financing cash flow has been positive, driven by external funding, reliance on external capital is not sustainable long-term.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	0.00
	Gross Profit
-9.38K	-681.43K	-11.11K	-2.13K	0.00	0.00
	EBIT
-1.19M	-2.71M	-3.64M	-852.81K	-136.95K	-72.00
	EBITDA
-3.45M	-2.71M	-3.57M	-847.50K	-1.81K	-3.37K
	Net Income Common Stockholders
-3.51M	-2.97M	-20.35M	-2.65M	-139.99K	-3.44K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
29.26K	12.56K	88.53K	1.35M	38.23K	2.24K
	Total Assets
62.75K	71.48K	504.14K	2.58M	147.22K	5.61K
	Total Debt
0.00	964.75K	101.77K	0.00	27.50K	0.00
	Net Debt
-29.26K	952.19K	13.24K	-1.35M	-10.73K	-2.24K
	Total Liabilities
1.71M	2.22M	719.25K	334.45K	136.27K	3.17K
	Stockholders Equity
-1.64M	-2.14M	-215.11K	2.24M	10.95K	2.44K
Cash Flow		Free Cash Flow
-369.79K	-1.57M	-2.79M	-1.07M	-37.52K	―
	Operating Cash Flow
-369.79K	-1.57M	-2.78M	-1.06M	-37.52K	―
	Investing Cash Flow
0.00	-3.14K	-52.13K	-604.91K	-100.00K	0.00
	Financing Cash Flow
386.51K	1.50M	1.57M	2.97M	173.50K	0.00

PanGenomic Health, Inc. Class A Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.81
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:NARA, the sentiment is Positive. The current price of 0.81 is above the 20-day moving average (MA) of 0.45, above the 50-day MA of 0.31, and above the 200-day MA of 0.27, indicating a bullish trend. The MACD of 0.16 indicates Negative momentum. The RSI at 82.55 is Negative, neither overbought nor oversold. The STOCH value of 67.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:NARA.

PanGenomic Health, Inc. Class A Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.38B	3.27	-45.10%	3.30%	16.81%	0.02%
NEWU	42 Neutral	C$866.33K	―	56.02%	―	-36.40%	-21.88%
NDAT	39 Underperform	C$619.91K	―	-60.84%	―	-92.67%	20.42%
NARA	29 Underperform	C$5.18M	―	213.49%	―	―	71.97%
TMED	19 Underperform	C$813.17K	―	20.09%	―	―	-15.84%
CGNSF		$659.39K	―		―	―	―
TELE		$7.59M	―		―	―	―

PanGenomic Health, Inc. Class A Corporate Events

PanGenomic Health Reprices Warrants to Enhance Market Appeal

PanGenomic Health Inc. has announced a repricing of 4,300,464 share purchase warrants from $0.50 to $0.17 per share, following unanimous consent from warrant holders. This change aims to potentially accelerate the expiration of warrants if the stock price reaches or exceeds $0.23 for ten consecutive trading days, enhancing liquidity and possibly attracting more stakeholders.

PanGenomic Health Secures $750,000 via Private Placement Offering

PanGenomic Health Inc. has successfully completed a private placement offering, raising $750,000 through the issuance of 7,500,000 units at $0.10 per unit. The proceeds, consisting of $50,000 in cash and $700,000 in settled indebtedness, will be used for general corporate and working capital purposes. The offering included participation from certain directors and officers, constituting a related party transaction under Canadian regulations, but exempt from formal valuation and minority shareholder approval requirements.

PanGenomic Health Proposes Repricing of Warrants

PanGenomic Health Inc. announced its intention to reprice 4,300,464 outstanding share purchase warrants from $0.50 to $0.17 per share, pending unanimous approval from warrant holders. This adjustment could potentially impact PanGenomic’s financial strategy by encouraging the exercise of warrants, which may influence the company’s stock market performance and stakeholder interests.

PanGenomic Health’s $750K Private Placement Announcement

PanGenomic Health, Inc. has announced a private placement offering aimed at raising up to $750,000 through the issuance of 7.5 million units, priced at $0.10 each. This move is intended to generate funds and settle the company’s outstanding debts, with shareholders’ approval already secured. The offering includes the issuance of common shares and warrants, potentially doubling the company’s current share count.